Promoters and Public have reduced their holdings, with YOY declines of -2.18% and -2.22%, respectively, while sector averages show no change.

Institutional investment has increased by 1.80% YOY, indicating some confidence; however, this is insufficient to offset the overall negative sentiment.

Mankind Pharma's performance diverges from the sector, as leading stocks like SANOFICONR are experiencing significant institutional buying, highlighting Mankind's relative weakness.